PMID- 30906300
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20200824
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 10
DP  - 2019
TI  - HLA Class II Genes HLA-DRB1, HLA-DPB1, and HLA-DQB1 Are Associated With the 
      Antibody Response to Inactivated Japanese Encephalitis Vaccine.
PG  - 428
LID - 10.3389/fimmu.2019.00428 [doi]
LID - 428
AB  - Aim: The objective of this study was to evaluate the association of the human 
      leukocyte antigen (HLA) class II genes HLA-DRB1, HLA-DPB1, and HLA-DQB1 with the 
      humoral immune response elicited by inactivated Japanese encephalitis (JE) 
      vaccine (IJEV). Methods: A total of 373 individuals aged 3-12 years in the Inner 
      Mongolia Autonomous Region in China, who received two doses of IJEV at 0 and 7 
      days, were enrolled in the current study. Based on the individuals' specific JE 
      virus (JEV)-neutralizing antibodies (NAbs), they were divided into a seropositive 
      and a seronegative group. HLA-DRB1, HLA-DPB1, and HLA-DQB1 were genotyped using a 
      sequencing-based typing method. Next, the association of the HLA class II genes 
      and their haplotypes with antibody response was evaluated. Results: Based on 
      NAbs, a total of 161 individuals were classified as seropositive and 212 as 
      seronegative. DQB1(*)02:01 was significantly associated with JEV seropositivity 
      (P < 0.001, OR = 0.364, 95% CI: 0.221-0.600), while DQB1(*)02:02 was 
      significantly associated with JEV seronegativity (P = 5.03 x 10(-6), OR = 7.341, 
      95% CI: 2.876-18.736). The haplotypes DRB1(*)07:01-DPB1(*)04:01-DQB1(*)02:01, 
      DRB1(*)15:01-DPB1(*)02:01-DQB1(*)06:02, DRB1(*)07:01-DQB1(*)02:01, and 
      DPB1(*)02:01-DQB1(*)06:02 were very frequent in the seropositive group, while 
      DRB1(*)07:01-DPB1(*)17:01-DQB1(*)02:02, DRB1(*)07:01-DQB1(*)02:02, and 
      DPB1(*)17:01-DQB1(*)02:02 were very frequent in the seronegative group. The 
      presence of DRB1(*)01:01, DRB1(*)04:05, DRB1(*)09:01, DRB1(*)12:02, DRB1(*)13:02, 
      and DRB1(*)14:01 was associated with a higher geometric mean titer (GMT) of NAbs 
      than that of DRB1(*)11:01 at the DRB1 locus (P < 0.05). At the DPB1 locus, the 
      presence of DPB1(*)05:01 was associated with higher GMTs than that of 
      DPB1(*)02:01 and DPB1(*)13:01 (P < 0.05), and the presence of DPB1(*)04:01 and 
      DPB1(*)09:01 was associated with higher GMTs than that of DPB1(*)13:01 (P < 
      0.05). Conclusions: The present study suggests that HLA class II genes may 
      influence the antibody response to IJEV.
FAU - Yao, Yufeng
AU  - Yao Y
AD  - Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Kunming, China.
FAU - Yang, Huijuan
AU  - Yang H
AD  - Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Kunming, China.
AD  - Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious 
      Disease, Kunming, China.
FAU - Shi, Lei
AU  - Shi L
AD  - Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Kunming, China.
AD  - Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious 
      Disease, Kunming, China.
FAU - Liu, Shuyuan
AU  - Liu S
AD  - Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Kunming, China.
FAU - Li, Chuanying
AU  - Li C
AD  - Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Kunming, China.
FAU - Chen, Jun
AU  - Chen J
AD  - Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Kunming, China.
FAU - Zhou, Ziyun
AU  - Zhou Z
AD  - Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Kunming, China.
FAU - Sun, Mingbo
AU  - Sun M
AD  - Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Kunming, China.
AD  - Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious 
      Disease, Kunming, China.
FAU - Shi, Li
AU  - Shi L
AD  - Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Kunming, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190308
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (HLA-DP beta-Chains)
RN  - 0 (HLA-DPB1 antigen)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Japanese Encephalitis Vaccines)
SB  - IM
MH  - Antibodies, Neutralizing/*immunology
MH  - Child
MH  - Child, Preschool
MH  - Double-Blind Method
MH  - Female
MH  - Genotype
MH  - HLA-DP beta-Chains/genetics/*immunology
MH  - HLA-DQ beta-Chains/genetics/*immunology
MH  - HLA-DRB1 Chains/genetics/*immunology
MH  - Humans
MH  - *Japanese Encephalitis Vaccines
MH  - Male
PMC - PMC6418001
OTO - NOTNLM
OT  - HLA haplotype
OT  - antibody immune response
OT  - association
OT  - human leukocyte antigen class II genes
OT  - inactivated Japanese encephalitis virus vaccine
EDAT- 2019/03/25 06:00
MHDA- 2020/08/25 06:00
PMCR- 2019/01/01
CRDT- 2019/03/26 06:00
PHST- 2018/07/18 00:00 [received]
PHST- 2019/02/18 00:00 [accepted]
PHST- 2019/03/26 06:00 [entrez]
PHST- 2019/03/25 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2019.00428 [doi]
PST - epublish
SO  - Front Immunol. 2019 Mar 8;10:428. doi: 10.3389/fimmu.2019.00428. eCollection 
      2019.